



C4Diagnostics, awardee of the « Resilience » program, expands and industrializes its range of rapid tests for Covid-19 diagnosis in humans

February 10, 2021, Marseille, FRANCE - C4Diagnostics, a French biotech developing innovative tests to diagnose infectious diseases, announced today that it has been awarded the "Resilience" call for projects and will receive public funding to implement and industrialize its diagnostic solutions for the detection of SARS-Cov-2 in humans with rapid, sensitive and ready-to-use kits based on RT-LAMP technology.

C4Diagnostics is leveraging its expertise in the diagnosis of human infectious diseases, and in particular in Covid-19 testing, to address the many challenges posed by the pandemic. While global testing is being organized and an increasing number of people are being tested regularly, several issues remain:

- Relieve overcrowding in medical labs,
- Ensure reagents and disposables supply for diagnostics,
- Enable saliva swabs, less invasive than nasal or nasopharyngeal swabs,
- Shorten the turnaround time from sampling to result,
- Discriminate Covid-19 from influenza or other viral respiratory diseases for rapid patient sorting.


In the frame of the "Resilience" call for projects, the industry pillar of the French "France Relance" Plan, C4Diagnostics has been selected to take up these challenges through the following work program:

- Set up a production site for reagents and disposables for hospital and local testing labs, thus contributing to **French sovereignty for Covid-19 diagnostics**,
- Provide the **C4Covid-19 Central Lab kit** to medical labs, a RT-LAMP-based diagnostic kit as sensitive but faster than traditional RT-PCR and compatible with the standard equipment of any medical lab. The time saving of the RT-LAMP approach will increase the daily capacity of analyses by 50%,
- Launch **C4Covid-19 human kit**, a **salivary rapid diagnostic** test to enable on-site screening of people not eligible for nasopharyngeal swabs such as the elderly and the children,
- Offer hospital and local testing labs a **multiplexed and rapid kit**, based on RT-LAMP technology, enabling the simultaneous testing of a panel of respiratory viruses such as SARS-CoV-2 and the influenza virus.

In line with its efforts since the beginning of the pandemic, C4Diagnostics is carrying on this roadmap dictated by the urgent need have the means to match the Covid-19 health challenges.

*"The range of diagnostic solutions developed by our company all stem from field needs. **We believe in the power of diagnostic tools to better control the epidemic and improve people care.** Previous studies from our team have shown that the right diagnostic tools, at the right time, in the right place, enable us to put in place preventive measures that can stop the spread of Covid-19 clusters. Today, with the support from the "France Relance" Plan we can ramp up and deploy our solutions to help better manage this health crisis, pending effective vaccination coverage,"* stated Younes Lazrak, CEO of C4Diagnostics.

Currently, the diagnostic solutions developed by C4Diagnostics to fight Covid-19 are available in France but could be deployed in the coming weeks to the rest of Europe and North America.



Additional information

- [Announcement of the 34 awardee of the French "Relance France" Plan](#) (in French only)

About C4Diagnostics

C4Diagnostics is a French-based biotech specialized in the development of *in vitro* diagnostic tests for human infectious diseases for hospital and city medical labs. These innovative tests bring together sensitivity and rapidity: three to five times faster than conventional approaches and simple to implement, with no compromise on sensitivity and specificity. Its pipeline currently focuses on the diagnosis of Covid-19, Legionellosis, urinary tract infections (UTI) and antibiotic susceptibility tests (AST).

In addition, C4Diagnostics provides a service activity, called C4Environment, for the detection of SARS-CoV-2 virus in the environment (wastewater, air, surface) and has supported several Covid-19 surveillance and prevention campaigns since the beginning of the pandemic.

With its rapid and sensitive *in vitro* diagnostic tests, C4Diagnostics aims to become one of the main actors in the diagnosis of human infectious diseases and change the game in infectious disease care and management.

www.C4Diagnostics.com

Press contacts

Younes Lazrak

CEO

+33 (0) 771 793 280

Younes.Lazrak@C4Diagnostics.com

Louise Modo

Marketing & Communication Specialist

+33(0)7 84 83 71 21

Communication@C4Diagnostics.com

